Ewing SarcomaSymptoms, Doctors, Treatments, Advances & More
Learn About Ewing Sarcoma
Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor.
The most common mutation that causes Ewing sarcoma involves two genes, the EWSR1 gene on chromosome 22 and the FLI1 gene on chromosome 11. A rearrangement (translocation) of genetic material between chromosomes 22 and 11, written as t(11;22), fuses part of the EWSR1 gene with part of the FLI1 gene, creating the EWSR1/FLI1 fusion gene. This mutation is acquired during a person's lifetime and is present only in tumor cells. This type of genetic change, called a somatic mutation, is not inherited.
Approximately 3 per 1 million children each year are diagnosed with a Ewing sarcoma. It is estimated that, in the United States, 250 children are diagnosed with one of these types of tumor each year. Ewing sarcoma accounts for about 1.5 percent of all childhood cancers, and it is the second most common type of bone tumor in children (the most common type of bone cancer is called osteosarcoma).
This condition is generally not inherited but arises from a mutation in the body's cells that occurs after conception. This alteration is called a somatic mutation.
The Children's Hospital At Montefiore
David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children’s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer. Dr. Loeb is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, and Bone Tumor.
Aurora Orthopedics
Nicholas Webber is an Orthopedics provider practicing medicine in Milwaukee, Wisconsin. Dr. Webber is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Osteoarthritis, Osteonecrosis, Rhabdomyosarcoma Embryonal, Hip Replacement, and Knee Replacement. Dr. Webber is board certified in American Board Of Orthopaedic Surgery.
C. S. Mott Children's Hospital
Patrick Grohar is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Grohar is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Rhabdoid Tumor. Dr. Grohar is board certified in Pediatric Hematology-Oncology.
Summary: The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.
Summary: This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any location in the body, such as the uterus or in the abdomen. Current standard treatment for leiomyosar...
Published Date: June 01, 2016
Published By: National Institutes of Health